" class="no-js "lang="en-US"> FUJIFILM Irvine Scientific Opens European Manufacturing Facility - Medtech Alert
Friday, March 01, 2024

FUJIFILM Irvine Scientific Opens European Manufacturing Facility

FUJIFILM Irvine Scientific, Inc., today announced that its new manufacturing facility in Tilburg, the Netherlands is now open and fully operational. The facility provides state-of-the-art Life Science manufacturing and joins locations in the U.S. and Japan to enable increased production capacity of cell culture media products; acting as a hub for both European and global markets.

Opening this third manufacturing facility fulfills an important step in the Company’s long-term plans to secure its production capacity to meet the growing needs of the market and customers worldwide. The facility’s location in central Europe positions it as a source of local supply for increased efficiency and cost-savings in shipping, as well as securing the supply chain.

The facility is built with sustainable initiatives in mind, drawing on parent company’s Fujifilm Sustainability Value Plan 2030 for sustainable operations. Strategies in use that adhere to the plan include working towards a CO2-neutral status, using wind energy for the production process, and using sustainable technologies such as membrane bioreactors for wastewater purification.

Set within FUJIFILM Manufacturing Europe B.V., one of the main production sites for FUJIFILM, the facility occupies approximately 13,500 square meters of space previously utilized to manufacture film rolls. The world-class facility manufactures dry powder media, liquid media, buffers, and Water for Injection (WFI) in accordance with the same Quality System, raw materials, and expertise used in the Company’s facilities in the U.S. and Japan. Initially, it increases the Company’s production capacity with approximately 320,000 kg/year of dry powder media and greater than 470,000 L/year of liquids with the physical capacity to expand rapidly.

“We worked steadily to achieve milestones for construction, validation, and commissioning of this manufacturing facility,” said Yutaka Yamaguchi, chairman, and chief executive officer, FUJIFILM Irvine Scientific. “Even with the global challenges faced in recent years, FUJIFILM Irvine Scientific was determined to provide customers in Europe with local service that strengthens the supply chain and increases manufacturing capacity. It is extremely rewarding to see this commitment realized.”

The site intends to become an ISO 13485 certified manufacturing facility and follow cGMP, 21 CFR 820 for product manufacturing. For more information about commercial manufacturing, please visit https://www.irvinesci.com/fujifilm-manufacturing-europe-bv.

View a video of the facility in action:

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more